Who needs to know?
Patients, Hepatologists and Pharmaceutical companies- therapeutic strategies targeting NAFLD are likely to reduce this risk of developing T2DM.
Results
Patients with NAFLD were at a 1.5 times increased risk of developing CVD and 2.2 times increased risk of T2DM.